A relatively high incidence of CAR T-cell-associated HLH presenting with highly elevated levels of IL-18 was observed in the CD22 CAR T treatment of relapsing patients or those nonresponsive to CD19-targeted therapies (Lichtenstein et al., 2021) [105]. The gene discussed is IL18; the disease is hemophagocytic syndrome.